Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Ticker CODX · OTC · UT
Co-Diagnostics, Inc. is a U.S. business entity operating within the Surgical & Medical Instruments & Apparatus sector (SIC 3841). Publicly traded on the OTC under the ticker symbol CODX, the company is incorporated in Utah. Based on SEC EDGAR filings, CODX reported fiscal year 2024 revenue of $3.9M, reflecting a year-over-year decline of 42.5%. Our proprietary Semantic Risk Score of 14 indicates high transparency and low reporting risk, derived from the frequency and consistency of 10-K, 10-Q, and 8-K filing patterns. As part of the SIC 3841 classification, Co-Diagnostics, Inc. serves as a key benchmark for investors and analysts monitoring Utah corporate performance.
Comparison based on Standard Industrial Classification (SIC) mapping from SEC EDGAR filings.
Filing data sourced from SEC EDGAR signals. 10-K = annual report · 10-Q = quarterly · 8-K = material event.
⚠ Data quality note: Some metrics were filtered due to high volatility in XBRL tags. Only verified figures are shown below.
Co-Diagnostics, Inc. (CODX) — Key efficiency & solvency metrics · FY2024
Debt-to-Equity
Sector avg: 2.45
Current Ratio
Sector avg: 3.95
| Key Metric | Company | Industry Avg | Status |
|---|---|---|---|
| Total RevenueYoY: -42.5% | $3.9M | $1.38B | ▼ Lagging |
| Net IncomeYoY: -6.5% | $-37,639,008 | — | — |
| Debt-to-EquityTotal liabilities / stockholders equity. Lower = safer. | 0.18 | 2.45 | ▲ Stable |
| Current RatioCurrent assets / current liabilities. Above 1.0 = solvent. | 4.41 | 3.95 | ▲ Outperform |
Source: SEC EDGAR XBRL filings (10-K annual reports). Industry benchmarks derived from 116 companies in SIC 3841.
Disclaimer: All financial data is sourced from raw SEC EDGAR filings. Sprytne.com provides automated data visualization and algorithmic analysis for informational purposes only. This is NOT financial advice, a recommendation to buy/sell, or a guarantee of accuracy. Always verify data via official SEC sources before making investment decisions.
Federal Contracts
PURCHASE OF H1N1 BULK ANTIGEN VACCINE FROM NOVARTIS (CAN 1994001)
0001 50M COVID-19 ANTIGEN TEST KITS
COVID-19 TEST KITS
IGF::CL,CT::IGF CONTRACT W58RGZ-16-C-0008 IS HEREBY AWARDED AS AN UNDEFINITIZED CONTRACT FOR THE MODERNIZED TARGET ACQUISITION DESIGNATION SIGHT/PILOT NIGHT VISION SENSOR PERFORMANCE BASED LOGISTICS PROGRAM, INCLUSIVE OF OBSOLESCENCE MANAGEMENT, CRASH BATTLE DAMAGE SUPPORT/ CORPUS CHRISTI ARMY DEPOT SUPPORT, DEMAND DIAGNOSTICS AND CONTRACTOR SUPPLY SUPPORT ACTIVITIES BOTH THE CONTINENTAL UNITED STATES AND OUTSIDE THE CONTINENTAL UNITED STATES.
NOVARTIS MF59 BULK ADJUVANT (CAN 1993410)
THE STRATEGIC OBJECTIVE OF THE IDDS ACTIVITY IS TO STRENGTHEN THE DETECTION OF DISEASES OF PUBLIC HEALTH IMPORTANCE AND IDENTIFICATION OF AMR IN PRIORITY INFECTIOUS DISEASES, AND IMPROVE THE QUALITY OF REAL-TIME SURVEILLANCE SYSTEMS FOR EXISTING AND EMERGING PATHOGENS. IDDS ACTIVITY WILL DIRECTLY CONTRIBUTE TO THE GOALS AND STRATEGIC OBJECTIVES OF USAIDS INFECTIOUS DISEASE OFFICE IN THE GH BUREAU. THE CONTRACTOR WILL CONTRIBUTE TO THIS PURPOSE BY ADDRESSING THE FOLLOWING THREE OF THE IDDS ACTIVITIES IR 1 NATIONAL DIAGNOSTIC NETWORK STRENGTHENED TO BE ACCESSIBLE, ACCURATE, ADAPTABLE, TIMELY AND INTEGRATED, IR 2 NATIONAL INDICATOR- AND EVENT-BASED SURVEILLANCE SYSTEM DEVELOPED AND CAPABLE OF DETECTING EVENTS OF SIGNIFICANCE FOR PUBLIC HEALTH, ANIMAL HEALTH AND HEALTH SECURITY, AND IR 3 EVIDENCE-BASED GUIDANCE AND INNOVATIVE SOLUTIONS DEVELOPED AND APPLIED TO STRENGTHEN IN-COUNTRY DIAGNOSTIC NETWORKS AND SURVEILLANCE SYSTEMS.
CONTINUOUS DIAGNOSTICS AND MITIGATION CDM DASHBOARD ECOSYSTEM
CONTINUOUS DIAGNOSTICS AND MITIGATION CDM DATA SERVICES
HAMILTON COMPANY FOR MFG CAPACITY EXPANSION OF COVID-19 DHHS TESTING AND DIAGNOSTICS. THIS ACTION WAS IN SUPPORT OF DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS)
THE NATIONAL INSTITUTE OF HEALTH (NIH) LAUNCHED THE RAPID ACCELERATION OF DIAGNOSTICS (RADS) INITIATIVE TO SPEED INNOVATION IN THE DEVELOPMENT, COMMERCIALIZATION, AND IMPLEMENTATION OF TECHNOLOGIES TO SIGNIFICANTLY INCREASE THE U.S. TESTING CAPACIT
Source: USAspending.gov (Official Federal Award Data). Reflects prime contracts only. Last sync: 2026-03-30.
Compared to 151 peers in Surgical & Medical Instruments & Apparatus (SIC 3841)
Revenue
Net Margin
SEC EDGAR XBRL filings by fiscal year
Side-by-side financial showdown — revenue, margins, and growth.
Methodology & compliance note
Data is aggregated from SEC EDGAR and Secretary of State public records. Any analytics such as "market share" are statistical estimates (proxy models) and are not official audits, valuations, or investment advice. Sprytne.com is an independent data aggregator and is not affiliated with any government agency.Learn more →